Lung Cancer Targeted Therapy Panel (EGFR+ALK+ROS1)

This test measures the presence of specific immunohistochemical, genetic and molecular markers, including EGFR, ALK, and ROS1 in tissue samples. These markers help determine the most suitable targeted therapy options for patients with NSCLC.

• To identify the presence of EGFR mutations, ALK rearrangements, or ROS1 rearrangements in NSCLC
• To guide treatment decisions by determining eligibility for targeted therapies
• To monitor treatment response and detect any acquired resistance to targeted therapies

This test is recommended for patients with NSCLC who meet the following criteria:

• Patients with advanced or metastatic NSCLC
• Patients who may be candidates for targeted therapies
• Patients who have not undergone previous testing for EGFR mutations, ALK rearrangements, or ROS1 rearrangements

Abnormal results from this test may indicate the presence of genetic alterations, such as EGFR mutations, ALK rearrangements, or ROS1 rearrangements in NSCLC. These abnormalities can help guide treatment decisions, including targeted therapies. It is important to discuss the results with your doctor for further evaluation and personalised treatment planning.

• A small tissue sample from your lung will be collected through a biopsy.
• Tumour-containing tissue is fixed in 10% neutral buffered formalin and embedded in paraffin.
• The sample will be sent to the laboratory for analysis.
• Various immunohistochemistry (IHC), cytogenetic and molecular techniques, including Real-Time PCR and FISH will be used to detect EGFR mutations, ALK rearrangements, and ROS1 rearrangements.

• You may need to undergo a biopsy procedure to obtain the NSCLC tissue sample.
• Follow any instructions provided by your doctor.
• Inform your doctor about any ongoing treatments or medications you are taking.

• Comprehensive genetic profiling of NSCLC tumors
• PD-L1 testing to determine eligibility for immunotherapy
• Imaging tests such as CT scans or MRI to evaluate the extent of lung cancer

NSCLC Molecular Testing Panel or Lung Cancer Genetic Alterations Panel

Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer, accounting for around 80-85% of all cases. It includes several subtypes and is characterised by the presence of malignant cells in the tissues of the lungs.